The 80th Annual Meeting of the Japanese Society of Hematology

Session information

Print

Oral Session

Oral Session 3-11A AML: Clinical siginificance of genetic abnormalities

Sun. Oct 14, 2018 8:30 AM - 9:30 AM No.11 (Osaka International Convention Center, 10F 1004-5)

Chair: Masashi Sanada (Nagoya Medical Center, National Hospital Organization, Japan)

[OS3-11A-1] Identification of recurrent CCND3 mutations in MLL-rearranged acute myeloid leukemia

Hidemasa Matsuo1, Kenichi Yoshida2, Kazutaka Fukumura3, Yusuke Shiozawa4, Yasuhito Nannya2, June Takeda2, Hiroo Ueno2, Norio Shiba5,6, Genki Yamato5,7, Hiroshi Handa8, Yuichiro Ono9, Nobuhiro Hiramoto9, Takayuki Ishikawa9, Kensuke Usuki10, Ken Ishiyama11, Shuichi Miyawaki11, Hidehiro Itonaga12, Yasushi Miyazaki12, Machiko Kawamura13, Hiroki Yamaguchi14, Nobutaka Kiyokawa15, Daisuke Tomizawa15, Takashi Taga16, Akio Tawa17, Yasuhide Hayashi5,18, Hiroyuki Mano3, Satoru Miyano19, Yasuhiko Kamikubo1, Seishi Ogawa2, Souichi Adachi1 (1.Human Health Sciences, Kyoto Univ., Kyoto, Japan, 2.Pathology and Tumor Biology, Kyoto Univ., Kyoto, Japan, 3.Cellular Signaling, Tokyo Univ., Tokyo, Japan, 4.Pediatrics, Tokyo Univ., Tokyo, Japan, 5.Hematology/Oncology, Gunma Children's Medical Center, Gunma, Japan, 6.Pediatrics, Yokohama City University Hospital, Yokohama, Japan, 7.Pediatrics, Gunma University Graduate School of Medicine, Gunma, Japan, 8.Hematology, Gunma University Graduate School of Medicine, Gunma, Japan, 9.Hematology, Kobe City Medical Center General Hospital, Kobe, Japan, 10.Hematology, NTT Medical Center, Tokyo, Japan, 11.Hematology, Tokyo Metropolitan Ohtsuka Hospital, Tokyo, Japan, 12.Hematology, Nagasaki University, Nagasaki, Japan, 13.Hematology, Saitama Cancer Center, Saitama, Japan, 14.Hematology, Nippon Medical School, Tokyo, Japan, 15.National Research Institute for Child Health and Development, Tokyo, Japan, 16.Pediatrics, Shiga University of Medical Science, Otsu, Japan, 17.Pediatrics, Osaka National Hospital, Osaka, Japan, 18.Japanese Red Cross Gunma Blood Center, Gunma, Japan, 19.Laboratory of DNA Information Analysis, Tokyo Univ., Tokyo, Japan)

[OS3-11A-2] Clinical significance and prognostic analyses of PTPN11, RAS, and CBL mutations in pediatric AML

Taeko Kaburagi1,2, Genki Yamato1,2,3, Norio Shiba2,3,4, Yusuke Hara2,3,5, Kentaro Ohki2,6, Manabu Sotomatsu1,2, Hirokazu Arakawa5, Nobutaka Kiyokawa2,6, Daisuke Tomizawa2,7, Souichi Adachi2,8, Takashi Taga2,9, Keizo Horibe2,3, Yasuhide Hayashi1,2,3,10 (1.Dept. Hematology/Oncology, Gunma Children's Medical Center, Gunma, Japan., 2.Japan Children's Cancer Group, 3.Clinical Research Center, Nagoya Medical Center, Aichi, Japan., 4.Dept. Pediatrics, Yokohama City University Hospital, Kanagawa, Japan., 5.Dept. Pediatrics, Gunma University Graduate School of Medicine, Gunma, Japan., 6.Natl. Cent. For Child Health and Dev., Tokyo, Japan, 7.Div. Leukemia and Lymphoma, Children's Cancer Center, NCCHD, Tokyo, Japan., 8.Human Health Science, Kyoto University, Kyoto, Japan., 9.Dept. Pediatrics, Shiga University of Medical Science, Shiga, Japan., 10.Institute of Physiology and Medicine, Jobu University)

[OS3-11A-3] Clonal evolution predicts the post-transplantation outcome in acute myeloid leukemia

Hiroki Yokoyama1, Takeshi Saito1, Takaki Shimada1, Jiro Minami1, Atsushi Katsube1, Yutaro Kamiyama1, Kazuhito Suzuki1, Ryoko Fukushima1, Hiroto Ishii1, Shoko Ishii1, Tadahiro Gunji1, Aya Nakano1, Masaharu Kawashima1, Susumu Tanoue1, Hideki Uryu1, Rika Hosoba1, Daiki Hattori1, Kurumi Ishimi1, Nobuaki Dobashi2, Noriko Usui2, Shingo Yano1 (1.Clin. Oncol. Hematol. Div., Jikei Univ., Tokyo, Japan, 2.Clin. Oncol. Hematol. Div., Jikei Daisan., Tokyo, Japan)

[OS3-11A-4] Clinical features and prognostic impact of TP53 mutations in the myeloid malignancies

Takuto Mori1, Yuichiro Ono1, Hayato Maruoka2, Madoka Kato1, Atsushi Tanaka1, Mari Morita1, Momoko Nakamura1, Yoshimitsu Shimomura1, Nobuhiro Hiramoto1, Satoshi Yoshioka1, Noboru Yonetani1, Akiko Matsushita1, Hisako Hashimoto1, Takayuki Ishikawa1 (1.Hematol, Kobe City Medical Center General Hospital, Hyogo, Japan, 2.Clin Lab, Kobe City Medical Center General Hospital, Hyogo, Japan)

[OS3-11A-5] The clinical features of Japanese de novo AML with RAS signal transduction pathway genes mutation

Shunsuke Yui1, Hiroki Yamaguchi1, Toshimitsu Ueki2, Kensuke Usuki3, Yutaka Kobayashi4, Kenji Tajika5, Seiji Gomi5, Saiko Kurosawa6, Atsushi Marumo1, Ikuko Omori1, Yusuke Fujiwara1, Masahiro Sakaguchi1, Satoshi Wakita1, Kunihito Arai1, Tomoaki Kitano1, Takahiro Fukuda6, Koiti Inokuchi1 (1.Department of Hematology, Nippon Medical School, Tokyo, Japan, 2.Department of Hematology, Nagano Red Cross Hospital, Nagano, 3.Department of Hematology, NTT Medical Center, Tokyo, 4.Department of Hematology, Kyoto Second Red Cross Hospital, Kyoto, 5.Department of Hematology, Yokohama Minami Kyousai Hospital, Kanagawa, 6.Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo)

[OS3-11A-6] Usefulness of a NPM1 mutation detection for assessment of minimal residual disease in AML

Kenta Date1, Atsushi Marumo1, Marika Kuboyama1, Kensuke Usuki2, Shinichi Kako3, Hitoji Uchiyama4, Katsuhiro Shono5, Yuho Najima6, Saiko Kurosawa7, Masahiro Sakaguchi1, Shunsuke Yui1, Satoshi Wakita1, Kunihito Arai1, Tomoaki Kitano1, Kazuhiko Kakihana6, Takahiro Fukuda7, Kazuteru Ohashi6, Hiroki Yamaguchi1, Koiti Inokuchi1 (1.Hematology, Nippon Medical School, Tokyo, Japan, 2.Hematology, NTT Medical Center Tokyo, Tokyo, Japan, 3.Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan, 4.Hematology, Japanese Red Cross Kyoto Daiichi Hospital, Kyoto, Japan, 5.Hematology, Chiba Aoba Municipal Hospital, Chiba, Japan, 6.Hematology, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan, 7.Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan)